Loading...
XSHE
300966
Market cap424mUSD
Oct 09, Last price  
24.75CNY
1D
0.53%
1Q
-17.86%
IPO
-41.13%
Name

Hubei Goto Biopharm Co Ltd

Chart & performance

D1W1MN
XSHE:300966 chart
P/E
—
P/S
4.71
EPS
—
Div yield, %
0.06%
Shrs. gr., 5y
1.65%
Rev. gr., 5y
0.51%
Revenues
606m
+12.97%
333,692,153437,301,669464,801,920468,117,263590,885,338590,885,338604,571,473604,571,472566,399,208536,595,591606,178,267
Net income
-73m
L+165.88%
47,438,68470,677,87772,996,36253,288,52578,330,63578,330,64240,205,16040,205,16123,005,020-27,591,125-73,359,121
CFO
41m
P
008,502,36613,474,98758,004,300068,132,538-20,588,44741,036,390
Dividend
Jul 16, 20260.045 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hubei Goto Biopharm Co.,Ltd. is a Chinese enterprise specializing in the manufacture and distribution of active pharmaceutical ingredients (APIs) and intermediate compounds for steroid hormones. Its product line features essential starting materials such as 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), sitolactone, 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD). The company also provides a variety of intermediates, including those for estrogens, progesterone, non-steroidal substances, various other hormones, and corticosteroids. Furthermore, Hubei Goto Biopharm supplies additional raw materials for the pharmaceutical industry. The firm was established in Yicheng, China, in 2006.

Key people

Wenjing Chen
Deputy General Manager, Secretary of the Board · since 2018
Minglei Li
Deputy General Manager, Director · since 2008
Xiangdong Liu
Chief Financial Officer, Director · since 2018
Xueming Wang
Director · since 2021
Zubin Xi
Chairman of the Board, General Manager, Director of R&D · since 2021
Deliang He
Independent Director · since 2024
Independent Director · since 2024
Independent Director · since 2024
IPO date
Apr 09, 2021
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
湖北省宜城市小河镇高坑一组
宜昌市, HB 441400
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT